Skip to main content
Equibles
AVXL logo

AVXL · Anavex Life Sciences Corp. · Metrics

Track AVXL — free

Use AVXL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AVXL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.33 -0.03 (-2.21%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$120.97M
Shares
92.70M
Volume · Oct 23 627.22K Avg daily vol (3M) 1.03M

AVXL metrics

58 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.33
Market cap
$120.97M

Price action

20 metrics
Price change (1W)
-8.1%
Price change (30D)
-44.9%
Price change (3M)
-45.2%
Price change (6M)
-58.9%
Price change (YTD)
-61.8%
Price change (1Y)
-85.5%
Trailing year
Price change (5Y)
-92.4%
52-week high
$9.35
52-week low
$1.25
Change from 52-week high
-85.5%
Change from 52-week low
+8.8%
Annualized volatility
89.4%
Annualized volatility (3M)
76.2%
Beta
1.9
RSI (14D)
23.8
Price vs SMA 50
-42.8%
Price vs SMA 200
-57.3%
Avg volume (3M)
1.04M
Relative volume
1.0
Average dollar volume
$2.45M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
92.70M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.1
reciprocal yield 89.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-25

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$17.37M
Net income (TTM)
−$13.02M
Trailing 12 months
Diluted EPS (TTM)
$-0.15
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.31

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.6%
Return on assets
-10.8%
Debt / equity
0.0
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
4.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$118.33M
Latest balance sheet
Cash & equivalents
$118.33M
Total assets
$120.14M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$29.29M
Capital expenditures (TTM)
—
R&D (TTM)
$26.10M
SG&A (TTM)
$10.00M
Stock compensation (TTM)
−$11.94M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
182
13F filer change QoQ
-12
Institutional ownership
41.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
7.4%
Private-fund adviser ownership
7.2%
Active holders' share change QoQ
-5.8%
Holder tenure
13.4
Price vs estimated holder cost
-54.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
14.5%

Short interest

3 metrics
Short interest
14.6%
Latest settlement · 13.6 days to cover
Days to cover
13.6d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1314052 CUSIP 032797300 13F (30d) 24 filings 24 filers Visit website Investor relations